Sage Therapeutics Reorganizes Its Business Operations To Support Ongoing Launch Of Zurzuvae In Postpartum Depression And Focus Pipeline Development Efforts Ahead Of A Clinical Study Readout For Dalzanemdor In Huntington's Disease Expected Later This Year, Plans Workforce Reduction Of ~33%

Benzinga · 10/17 11:06

The reorganization is planned to be substantially completed by the end of the 4th quarter of 2024 and expected to:

  • Impact over 165 employees (approximately 33% of the company's total workforce and approximately 55% of the company's R&D workforce), including changes to the leadership team
  • Implement early-stage pipeline prioritization